EUVIMEDEUVIMED entdecken
Crossref

β-Cell Function and Sensitivity to Incretins Before and After Roux-en-Y Gastric Bypass in Individuals With Type 2 Diabetes

Maria S Svane iD, Morten Hindsø iD, Christoffer Martinussen iD, Carsten Dirksen, Nils B Jørgensen, Nora Hedbäck, Bolette Hartmann iD, Viggo B Kristiansen, Jens J Holst iD, Kirstine N Bojsen-Møller, Sten Madsbad iD

Diabetes · 2025

DOI: 10.2337/db24-1054 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, 2025. Verfasst von Maria S Svane und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Hvidovre Hospital, Copenhagen University, Hvidovre, Denmark. Hauptthemen laut MEDLINE: Gastric Bypass, Diabetes Mellitus, Type 2, Insulin-Secreting Cells, Incretins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: European Research Council, European Unions's Horizon 2020 research and grant innovation program, Novo Nordisk Fonden, The Danish Diabetes Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Roux-en-Y gastric bypass (RYGB) improves glucose tolerance in patients with type 2 diabetes, but the effect on β-cell sensitivity to glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) remains unclear. We performed oral glucose tolerance tests (OGTTs) and hyperglycemic clamps (at 15 mmol/L) with GIP, GLP-1, or saline coinfusions before and 1 week and 3 months after RYGB in nine patients with preoperative type 2 diabetes. During OGTTs, fasting plasma glucose normalized, while glucose tolerance, GLP-1, and insulin secretion increased markedly after RYGB. During clamped hyperglycemia with saline coinfusion, first- and second-phase insulin secretion increased after RYGB. GLP-1 and GIP coinfusions clearly potentiated insulin secretion before and after surgery, but the potentiation of insulin secretion, expressed relative to insulin secretion during saline coinfusion, was reduced after surgery during GLP-1 (first- and second-phase insulin secretion) and GIP (only first-phase insulin secretion) coinfusion. Thus, insulin secretion increased in response to oral and i.v. glucose, but the sensitivity of the β-cell to GLP-1 seemed reduced after RYGB. Accordingly, the improved β-cell function after RYGB in patients with preoperative type 2 diabetes is driven by enhanced GLP-1 secretion upon oral stimulation and improved β-cell response to glucose, but not an improved sensitivity of the β-cells to incretins. ARTICLE HIGHLIGHTS Roux-en-Y gastric bypass improves glycemic control in patients with type 2 diabetes, but the impact of the improved glycemic control on β-cell sensitivity to glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) is sparsely described. GLP-1 and GIP potentiated insulin secretion during clamped hyperglycemia before and after surgery, but, when related to the response to glucose alone, the relative potentiating effects of GIP (on first-phase insulin secretion) and GLP-1 (on first- and second-phase insulin secretion) were reduced postoperatively. The improvement in β-cell function after Roux-en-Y gastric bypass in patients with type 2 diabetes is not driven by improved β-cell sensitivity to incretins but rather other factors, including improved β-cell sensitivity to the changed glucose response and exaggerated postprandial GLP-1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastric BypassDiabetes Mellitus, Type 2Insulin-Secreting CellsIncretinsHumansGlucagon-Like Peptide 1Gastric Inhibitory PolypeptideBlood GlucoseInsulinInsulin SecretionMaleFemale

Substanzen

IncretinsGlucagon-Like Peptide 1Gastric Inhibitory PolypeptideBlood GlucoseInsulin

Autor:innen und Institutionen

  • Department of Endocrinology, Hvidovre Hospital, Copenhagen University, Hvidovre, Denmark.
  • Department of Surgical Gastroenterology, Hvidovre Hospital, Copenhagen University, Hvidovre, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

ORCID-Profile: Maria S Svane, Morten Hindsø, Christoffer Martinussen, Bolette Hartmann, Jens J Holst, Sten Madsbad

Förderung

  • European Research Council, European Unions's Horizon 2020 research and grant innovation program
  • Novo Nordisk Fonden
  • The Danish Diabetes Association
  • Novo Nordisk Foundation Center for Basic Metabolic Research University of Copenhagen

Zitieren

APA

Svane, M. S., Hindsø, M., Martinussen, C., Dirksen, C., Jørgensen, N. B., Hedbäck, N., Hartmann, B., Kristiansen, V. B., Holst, J. J., Bojsen-Møller, K. N., & Madsbad, S. (2025). β-Cell Function and Sensitivity to Incretins Before and After Roux-en-Y Gastric Bypass in Individuals With Type 2 Diabetes. Diabetes. https://doi.org/10.2337/db24-1054

Vancouver

Svane MS, Hindsø M, Martinussen C, Dirksen C, Jørgensen NB, Hedbäck N, et al. β-Cell Function and Sensitivity to Incretins Before and After Roux-en-Y Gastric Bypass in Individuals With Type 2 Diabetes. Diabetes. 2025. doi:10.2337/db24-1054

BibTeX
@article{Svane2025,
  author = {Svane, Maria S and Hindsø, Morten and Martinussen, Christoffer and Dirksen, Carsten and Jørgensen, Nils B and Hedbäck, Nora and Hartmann, Bolette and Kristiansen, Viggo B and Holst, Jens J and Bojsen-Møller, Kirstine N and Madsbad, Sten},
  title = {β-Cell Function and Sensitivity to Incretins Before and After Roux-en-Y Gastric Bypass in Individuals With Type 2 Diabetes},
  journal = {Diabetes},
  year = {2025},
  doi = {10.2337/db24-1054}
}
Kostenlos starten →